For the year ending 2025-07-31, RFL-WT had $50,094K increase in cash & cash equivalents over the period. -$18,928K in free cash flow.
| Cash Flow | 2025-07-31 |
|---|---|
| Loss (gain) on sale of property and equipment | -81 |
| Amortization of discount on available-for-sale securities | -285 |
| Unrealized loss (gain) on equity investments - cyclo | -5,144 |
| Change in deferred income taxes | -165 |
| Stock-based compensation | 2,123 |
| Gain on dtlm sale transactions | 30 |
| Trade accounts receivable | 151 |
| Interest receivable | -515 |
| Inventory | 11 |
| Prepaid expenses and other current assets | -818 |
| Prepaid clinical costs (current and non-current) | -112 |
| Other receivables | 273 |
| Other assets | -28 |
| Accounts payable and accrued expenses | -922 |
| Other current liabilities | -67 |
| Due to related parties | -10 |
| Accrued expenses, noncurrent | 913 |
| Convertible notes payable | 5 |
| Other liabilities | 15 |
| Consolidated net loss | -30,643 |
| Depreciation and amortization | 288 |
| Loss on impairment of goodwill | 3,050 |
| Realized gain on available-for-sale securities | 178 |
| Unrealized loss (gain) on convertible notes receivable, due from cyclo | -719 |
| Net unrealized gain on investments - hedge funds | 0 |
| Realized loss on investment in equity securities | 0 |
| Loss on initial investment in day three upon acquisition | 0 |
| Realized gain on equity investments - cyclo | 0 |
| Recovery of receivables from cornerstone | 0 |
| In-process research and development expense | 0 |
| Gain on dissolution of a business | 0 |
| Equity in loss of day three | 0 |
| Credit loss expense | 0 |
| Net cash used in operating activities | -18,924 |
| Purchase of property and equipment | 4 |
| Proceeds from sale of property and equipment | 13 |
| Purchases of available-for-sale securities | 16,988 |
| Proceeds from the sale and maturities of available-for-sale securities | 80,694 |
| Purchase of intangible assets | 17 |
| Payments for convertible notes receivable, due from cyclo | 19,500 |
| Cash paid in cyclo merger, net of cash acquired | 2,709 |
| Proceeds from hedge funds | 2,547 |
| Proceeds from day three patent sale | 0 |
| Proceeds from sales of equity securities | 0 |
| Issuance of convertible notes receivable, due from cyclo | 0 |
| Purchase of investments in cyclo | 0 |
| Issuance of convertible note receivable | 0 |
| Issuance of day three promissory notes | 0 |
| Proceeds from investments - other pharmaceuticals | 0 |
| Cash acquired in acquisition of day three, net of cash payments | 0 |
| Cash acquired in the cornerstone acquisition, net of cash payments | 0 |
| Net cash provided by (used in) investing activities | 44,035 |
| Payments for taxes related to shares withheld for employee taxes | 215 |
| Proceeds from issuance of common stock in rights offering, net of transaction costs | 25,001 |
| Proceeds from sale of rafael medical devices membership units | 44 |
| Principal payments on installment note payable | 0 |
| Purchases of treasury stock | 0 |
| Net cash provided by (used in) financing activities | 24,830 |
| Effect of exchange rate changes on cash and cash equivalents | 153 |
| Net increase (decrease) in cash and cash equivalents | 50,094 |
| Cash and cash equivalents at beginning of period | 2,675 |
| Cash and cash equivalents at end of period | 52,769 |
Rafael Holdings, Inc. (RFL-WT)
Rafael Holdings, Inc. (RFL-WT)